Chemours Co (NYSE:CC) VP Mark Newman sold 59,210 shares of Chemours stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $38.26, for a total value of $2,265,374.60. Following the completion of the transaction, the vice president now owns 94,261 shares of the company’s stock, valued at $3,606,425.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of CC stock opened at $38.61 on Friday. The company has a debt-to-equity ratio of 3.88, a current ratio of 1.93 and a quick ratio of 1.26. Chemours Co has a 52 week low of $25.17 and a 52 week high of $53.25. The company has a market capitalization of $6.51 billion, a price-to-earnings ratio of 6.81, a P/E/G ratio of 0.53 and a beta of 2.31.

Chemours (NYSE:CC) last issued its earnings results on Thursday, February 14th. The specialty chemicals company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.04 by $0.01. Chemours had a return on equity of 98.83% and a net margin of 14.99%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the previous year, the firm posted $1.19 earnings per share. Chemours’s quarterly revenue was down 7.0% compared to the same quarter last year. On average, analysts predict that Chemours Co will post 4.69 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 15th. Shareholders of record on Wednesday, February 27th will be paid a $0.25 dividend. The ex-dividend date of this dividend is Tuesday, February 26th. This represents a $1.00 dividend on an annualized basis and a yield of 2.59%. Chemours’s payout ratio is currently 17.64%.

A number of research firms recently commented on CC. ValuEngine upgraded Chemours from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 20th. Citigroup restated a “buy” rating and issued a $43.00 target price on shares of Chemours in a research note on Wednesday, February 20th. Barclays restated a “buy” rating and issued a $48.00 target price on shares of Chemours in a research note on Tuesday, January 15th. Zacks Investment Research downgraded Chemours from a “hold” rating to a “sell” rating in a research note on Friday, January 4th. Finally, Susquehanna Bancshares restated a “neutral” rating and issued a $37.00 target price on shares of Chemours in a research note on Tuesday, February 19th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $48.13.

A number of hedge funds have recently modified their holdings of CC. Financial Architects Inc raised its holdings in shares of Chemours by 39.2% during the fourth quarter. Financial Architects Inc now owns 1,421 shares of the specialty chemicals company’s stock valued at $40,000 after buying an additional 400 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Chemours by 6.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 10,405 shares of the specialty chemicals company’s stock valued at $294,000 after buying an additional 667 shares during the last quarter. Texas Permanent School Fund raised its holdings in shares of Chemours by 0.6% during the fourth quarter. Texas Permanent School Fund now owns 111,956 shares of the specialty chemicals company’s stock valued at $3,159,000 after buying an additional 684 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Chemours by 5.6% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 17,043 shares of the specialty chemicals company’s stock valued at $481,000 after buying an additional 906 shares during the last quarter. Finally, Advisor Partners LLC raised its holdings in shares of Chemours by 13.8% during the fourth quarter. Advisor Partners LLC now owns 8,362 shares of the specialty chemicals company’s stock valued at $236,000 after buying an additional 1,014 shares during the last quarter. Institutional investors own 79.49% of the company’s stock.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2019/03/15/mark-newman-sells-59210-shares-of-chemours-co-cc-stock.html.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Story: Is it better to buy a fund with a higher or lower NAV?

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.